Latest1 information on COVID-19
©2022 Stanford Medicine
Continuous Glucose Monitoring in Pregnant Women Undergoing Betamethasone Therapy
Not Recruiting
Trial ID: NCT01165775
Purpose
We hope to clarify how betamethasone affects glucose levels in the mother in the days after
receiving the drug. This understanding will hopefully allow us to better anticipate the risk
of maternal hyperglycemia and therefore establish more appropriate monitoring of maternal
glucose to prevent maternal and neonatal complications of hyperglycemia.
Official Title
Continuous Glucose Monitoring in Pregnant Women Undergoing Betamethasone Therapy
Stanford Investigator(s)
Yasser El-Sayed, Professor
Charles B. and Ann L. Johnson Professor in the School of Medicine and Professor, by courtesy, of Pediatrics (Neonatology) and of Surgery
Eligibility
Inclusion Criteria:- 18 years of age or older
- Receiving betamethasone as part of routine clinical care.
- Pregnancy between 23+5 and 35+0 weeks Exclusion Criteria:- Less than 18 years old.
- Major fetal anomalies
- Use of steroid medications in the past 2 weeks.
Intervention(s):
device: Dexcom Seven Plus Continuous Glucose Monitoring System
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Yasser El-Sayed
6507233198